1548 logo

Genscript Biotech Corporation Stock Price

SEHK:1548 Community·HK$30.1b Market Cap
  • 2 Narratives written by author
  • 0 Comments on narratives written by author
  • 11 Fair Values set on narratives written by author

1548 Share Price Performance

HK$13.74
2.90 (26.75%)
HK$18.56
Fair Value
HK$13.74
2.90 (26.75%)
26.0% undervalued intrinsic discount
HK$18.56
Fair Value
Price HK$13.74
AnalystConsensusTarget HK$18.56
AnalystLowTarget HK$15.88

1548 Community Narratives

AnalystConsensusTarget·
Fair Value HK$18.56 26.0% undervalued intrinsic discount

Automation And Global Capacity Will Reshape Biologics Market

0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AnalystLowTarget·
Fair Value HK$15.88 13.5% undervalued intrinsic discount

Heavy Automation Costs And Legend Exposure Will Slowly Give Way To Healthier Margins

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
HK$15.88
13.5% undervalued intrinsic discount
Profit Margin
10.84%
Future PE
49.87x
Price in 2029
HK$20.14

Trending Discussion

Updated Narratives

1548 logo

1548: European mRNA Expansion And AI Integration Will Support Future Upside Potential

Fair Value: HK$18.56 26.0% undervalued intrinsic discount
2 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
1548 logo

Heavy Automation Costs And Legend Exposure Will Slowly Give Way To Healthier Margins

Fair Value: HK$15.88 13.5% undervalued intrinsic discount
0 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Very undervalued with excellent balance sheet.

0 Risks
4 Rewards

Genscript Biotech Corporation Key Details

US$959.5m

Revenue

US$406.3m

Cost of Revenue

US$553.2m

Gross Profit

US$1.1b

Other Expenses

-US$532.8m

Earnings

Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
n/a
-0.24
57.65%
-55.53%
7.1%
View Full Analysis

About 1548

Founded
2002
Employees
6165
CEO
Weihui Shao
WebsiteView website
www.genscript.com

Genscript Biotech Corporation, an investment holding company, engages in the manufacture and sale of life science research products and services in the United States of America, Europe, Mainland China, Europe, Asia Pacific, and internationally. It operates through Life Science Services and Products; Biologics Development Services; and Industrial Synthetic Biology Products segments. The Life Science Services and Products segment provide research services and products which are used in fundamental to life-science research and application. The Biologics Development Services segment which helps biopharmaceutical and biotech companies accelerate the development of therapeutic antibodies, and gene/cell therapy products with an integrated platform. The Industrial Synthetic Biology Products segment develops and produces industrial enzymes through non-pathogenic microbial strains constructed using genetic engineering. It also offers SurePAGE, a precast gel series; CytoSinct, a Nanobeads product and services; and Benz-Neburase, a genetically engineered endonuclease. In addition, the company provides automated protein and antibody purification system; automated maxi-plasmid purification; automated mini-scale purification for plasmid, protein, and antibody; eBlot and eStain, a protein transfer and staining system; eZwest Lite, an automated western blotting device; CytoSinct, a cell isolation solution; pharmacokinetics and immunogenicity ELISA kits; COVID-19 detection cPass technology kits; and GenBox, a mini electrophoresis tank. It serves antibody drug discovery; gene therapy; vaccine; in vitro diagnostics; gene editing; plant biology; and synthetic biology solutions. The company was founded in 2002 and is headquartered in Wanchai, Hong Kong.